Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia

Abstract Antipsychotic drugs target primarily dopaminergic system which makes catechol-O-methyltransferase (COMT) an interesting target in studies searching for treatment response predictors in schizophrenia. The study assessed the association of the COMT rs4680 and rs4818 polymorphisms with therape...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Matea Nikolac Perkovic, Marina Sagud, Maja Zivkovic, Suzana Uzun, Gordana Nedic Erjavec, Oliver Kozumplik, Dubravka Svob Strac, Ninoslav Mimica, Alma Mihaljevic Peles, Nela Pivac
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e01b3ae0ccde41b1b54d18ccf9da741e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e01b3ae0ccde41b1b54d18ccf9da741e
record_format	dspace
spelling	oai:doaj.org-article:e01b3ae0ccde41b1b54d18ccf9da741e2021-12-02T17:45:12ZCatechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia10.1038/s41598-020-67351-52045-2322https://doaj.org/article/e01b3ae0ccde41b1b54d18ccf9da741e2020-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-67351-5https://doaj.org/toc/2045-2322Abstract Antipsychotic drugs target primarily dopaminergic system which makes catechol-O-methyltransferase (COMT) an interesting target in studies searching for treatment response predictors in schizophrenia. The study assessed the association of the COMT rs4680 and rs4818 polymorphisms with therapeutic response to olanzapine, risperidone, clozapine or other antipsychotic medication after 8 weeks of monotherapy in patients with schizophrenia. 521 Caucasian patients with schizophrenia received a monotherapy with olanzapine (10–20 mg/day; N = 190), risperidone (3–6 mg/day; N = 99), or clozapine (100–500 mg/day; N = 102). The fourth group (N = 130) consisted of patients receiving haloperidol (3–15 mg/day), fluphenazine (4–25 mg/day) or quetiapine (50–800 mg/day). Treatment response was defined as a 50% reduction from the baseline positive and negative syndrome scale (PANSS) total and subscale scores, but also as an observed percentage reduction from the initial PANSS0–6 total and subscale scores. Carriers of the COMT rs4680 A allele and carriers of the COMT rs4680–rs4818 C-A haplotype block had greater reduction in the PANSS total scores following olanzapine treatment, compared to carriers of the COMT rs4680 GG genotype and other COMT rs4680–rs4818 haplotypes. The COMT rs4680 A allele, and COMT rs4680–rs4818 C-A haplotype, were significantly associated with therapeutic response in patients treated with olanzapine, but not in patients treated with other antipsychotics.Matea Nikolac PerkovicMarina SagudMaja ZivkovicSuzana UzunGordana Nedic ErjavecOliver KozumplikDubravka Svob StracNinoslav MimicaAlma Mihaljevic PelesNela PivacNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Matea Nikolac Perkovic Marina Sagud Maja Zivkovic Suzana Uzun Gordana Nedic Erjavec Oliver Kozumplik Dubravka Svob Strac Ninoslav Mimica Alma Mihaljevic Peles Nela Pivac Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia
description	Abstract Antipsychotic drugs target primarily dopaminergic system which makes catechol-O-methyltransferase (COMT) an interesting target in studies searching for treatment response predictors in schizophrenia. The study assessed the association of the COMT rs4680 and rs4818 polymorphisms with therapeutic response to olanzapine, risperidone, clozapine or other antipsychotic medication after 8 weeks of monotherapy in patients with schizophrenia. 521 Caucasian patients with schizophrenia received a monotherapy with olanzapine (10–20 mg/day; N = 190), risperidone (3–6 mg/day; N = 99), or clozapine (100–500 mg/day; N = 102). The fourth group (N = 130) consisted of patients receiving haloperidol (3–15 mg/day), fluphenazine (4–25 mg/day) or quetiapine (50–800 mg/day). Treatment response was defined as a 50% reduction from the baseline positive and negative syndrome scale (PANSS) total and subscale scores, but also as an observed percentage reduction from the initial PANSS0–6 total and subscale scores. Carriers of the COMT rs4680 A allele and carriers of the COMT rs4680–rs4818 C-A haplotype block had greater reduction in the PANSS total scores following olanzapine treatment, compared to carriers of the COMT rs4680 GG genotype and other COMT rs4680–rs4818 haplotypes. The COMT rs4680 A allele, and COMT rs4680–rs4818 C-A haplotype, were significantly associated with therapeutic response in patients treated with olanzapine, but not in patients treated with other antipsychotics.
format	article
author	Matea Nikolac Perkovic Marina Sagud Maja Zivkovic Suzana Uzun Gordana Nedic Erjavec Oliver Kozumplik Dubravka Svob Strac Ninoslav Mimica Alma Mihaljevic Peles Nela Pivac
author_facet	Matea Nikolac Perkovic Marina Sagud Maja Zivkovic Suzana Uzun Gordana Nedic Erjavec Oliver Kozumplik Dubravka Svob Strac Ninoslav Mimica Alma Mihaljevic Peles Nela Pivac
author_sort	Matea Nikolac Perkovic
title	Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia
title_short	Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia
title_full	Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia
title_fullStr	Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia
title_full_unstemmed	Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia
title_sort	catechol-o-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/e01b3ae0ccde41b1b54d18ccf9da741e
work_keys_str_mv	AT mateanikolacperkovic catecholomethyltransferasers4680andrs4818haplotypeassociationwithtreatmentresponsetoolanzapineinpatientswithschizophrenia AT marinasagud catecholomethyltransferasers4680andrs4818haplotypeassociationwithtreatmentresponsetoolanzapineinpatientswithschizophrenia AT majazivkovic catecholomethyltransferasers4680andrs4818haplotypeassociationwithtreatmentresponsetoolanzapineinpatientswithschizophrenia AT suzanauzun catecholomethyltransferasers4680andrs4818haplotypeassociationwithtreatmentresponsetoolanzapineinpatientswithschizophrenia AT gordananedicerjavec catecholomethyltransferasers4680andrs4818haplotypeassociationwithtreatmentresponsetoolanzapineinpatientswithschizophrenia AT oliverkozumplik catecholomethyltransferasers4680andrs4818haplotypeassociationwithtreatmentresponsetoolanzapineinpatientswithschizophrenia AT dubravkasvobstrac catecholomethyltransferasers4680andrs4818haplotypeassociationwithtreatmentresponsetoolanzapineinpatientswithschizophrenia AT ninoslavmimica catecholomethyltransferasers4680andrs4818haplotypeassociationwithtreatmentresponsetoolanzapineinpatientswithschizophrenia AT almamihaljevicpeles catecholomethyltransferasers4680andrs4818haplotypeassociationwithtreatmentresponsetoolanzapineinpatientswithschizophrenia AT nelapivac catecholomethyltransferasers4680andrs4818haplotypeassociationwithtreatmentresponsetoolanzapineinpatientswithschizophrenia
_version_	1718379618370584576

Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia

Ejemplares similares